Ocugen submits NDA with FDA to initiate phase 1 clinical trial evaluating OCU200 for treatment of DME
by: David Hutton The regulatory milestone fulfills the company’s goal to file the IND for OCU200 within the first quarter of 2023. Ocugen Inc. today announced that it has submitted…